Raffles Medical Set to Gain as Singapore Further Opens Borders -- Market Talk
Raffles Medical Set to Gain as Singapore Further Opens Borders -- Market Talk
0500 GMT - Raffles Medical Group is likely to benefit from the further reopening of Singapore's borders, given it is the sole provider of Covid-19 polymerase chain reaction tests at the country's Changi Airport, RHB Research says. The conversion of the Connect@Changi business facility into a Covid-19 community-care facility should also support near-term revenue growth, the broker says. The likely return of walk-in patients to clinics and inflow of more foreign patients into Singapore could further help, RHB Research says. It keeps a buy call on Raffles Medical and raises the target price to S$1.65 from S$1.45. Shares fall 1.3% to S$1.46. (yongchang.chin@wsj.com)
0500GMT-RHB Research表示，鑑於萊佛士醫療集團是新加坡樟宜機場新冠肺炎聚合酶鏈式反應檢測的唯一提供商，該集團可能會從新加坡邊境的進一步開放中受益。該經紀商表示，將Connect@Changi商業設施轉變為新冠肺炎社區護理設施，也應該會支持近期的收入增長。RHB Research説，無預約患者可能會回到診所，更多的外國患者湧入新加坡，這可能會進一步幫助患者。它繼續買入萊佛士醫療公司(Raffles Medical)的股票，並將目標價從1.45新元上調至1.65新元。股價下跌1.3%，至1.46新元。(yongchang.chin@wsj.com)
譯文內容由第三人軟體翻譯。